REGENERON PHARMACEUT

REGN
Delayed Quote. Delayed  - 09/24 04:00:00 pm
638.9USD -1.18%
Valuation
Fiscal Period: December 2020 2021
Capitalization1 50 99066 425
Entreprise Value (EV)1 50 09859 631
P/E ratio 15,8x10,1x
Yield --
Capitalization / Revenue 6,00x4,79x
EV / Revenue 5,90x4,30x
EV / EBITDA 11,8x7,07x
Price to Book 4,71x3,68x
Nbr of stocks (in thousands) 105 544103 968
Reference price (USD) 483639
Announcement Date 02/05/2021-
Previous period Next period
1 USD in Million
Estimates
Income Statement Evolution
Annual Income Statement Data
Fiscal Period: December 2020 2021
Net sales1 8 49713 869
EBITDA1 4 2458 439
Operating profit (EBIT)1 3 5777 501
Operating Margin 42,1%54,1%
Pre-Tax Profit (EBT)1 3 8108 251
Net income1 3 5136 943
Net margin 41,3%50,1%
EPS2 30,563,5
Dividend per Share2 --
Announcement Date 02/05/2021-
Previous period Next period
1 USD in Million
2 USD
Finances - Leverage
Fiscal Period: December 2020 2021
Net Debt1 --
Net Cash position1 8916 794
Leverage (Debt / EBITDA) -0,21x-0,81x
Free Cash Flow1 2 0045 208
ROE (Net Profit / Equities) 33,2%49,4%
Shareholders' equity1 10 59514 052
ROA (Net Profit / Asset) 22,0%31,5%
Assets1 15 98422 036
Book Value Per Share2 102173
Cash Flow per Share2 22,768,1
Capex1 615584
Capex / Sales 7,23%4,21%
Announcement Date 02/05/2021-
Previous period Next period
1 USD in Million
2 USD
Financial Ratios
Size 2021e 2022e
Capitalization 66 425 M $ -
Entreprise Value (EV) 59 631 M $ 57 143 M $
Valuation 2021e 2022e
P/E ratio (Price / EPS) 10,1x 14,8x
Capitalization / Revenue 4,79x 5,44x
EV / Revenue 4,30x 4,88x
EV / EBITDA 7,07x 9,26x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 3,68x 2,84x
Profitability 2021e 2022e
Operating Margin (EBIT / Sales) 54,1% 41,2%
Operating Leverage (Delta EBIT / Delta Sales) 1,74x -2,74x
Net Margin (Net Profit / Revenue) 50,1% 37,4%
ROA (Net Profit / Asset) 31,5% 18,9%
ROE (Net Profit / Equities) 49,4% 27,1%
Rate of Dividend - -
Balance Sheet Analysis 2021e 2022e
CAPEX / Sales   4,21% 4,94%
Cash Flow / Sales 51,0% 43,9%
Capital Intensity (Assets / Sales) 1,59x 1,98x
Financial Leverage (Net Debt / EBITDA) - -
Price Earning Ratio
Change in Enterprise Value/EBITDA
EPS & Dividend